Zobrazeno 1 - 10
of 145
pro vyhledávání: '"Gareth I Owen"'
Autor:
Jorge Jimenez de la Jara, Gabriel Bastias, Catterina Ferreccio, Cristian Moscoso, Sofia Sagues, Camilo Cid, Eduardo Bronstein, Cristian Herrera, Bruno Nervi, Alejandro Corvalan, Ethel V Velasquez, Pamela Gonzalez, Enrique Castellon, Eva Bustamante, Sergio Oñate, Eileen McNerney, Richard Sullivan, Gareth I Owen
Publikováno v:
Biological Research, Vol 48, Iss 0, Pp 1-10 (2015)
INTRODUCTION: The South American country Chile now boasts a life expectancy of over 80 years. As a consequence, Chile now faces the increasing social and economic burden of cancer and must implement political policy to deliver equitable cancer care.
Externí odkaz:
https://doaj.org/article/1392fb7834274dfc80718af6d1d352bb
Autor:
Rebecca Graumann, Gabriella A Di Capua, Juan E Oyarzún, Marcos A Vásquez, Christine Liao, Jorge A Brañes, Iván Roa, Paola Casanello, Alejandro H Corvalán, Gareth I Owen, Iris Delgado, Uwe Zangemeister-Wittke, Annemarie Ziegler
Publikováno v:
PLoS ONE, Vol 12, Iss 5, p e0177244 (2017)
Teneurins are a family of highly conserved pair-rule proteins involved in morphogenesis and development of the central nervous system. Their function in adult tissues and in disease is largely unknown. Recent evidence suggests a role for dysregulated
Externí odkaz:
https://doaj.org/article/a80979f14da9470da31008f97030491c
Autor:
Ricardo J Figueroa, Gonzalo Carrasco-Avino, Ignacio A Wichmann, Martin Lange, Gareth I Owen, Arndt F Siekmann, Alejandro H Corvalán, Juan C Opazo, Julio D Amigo
Publikováno v:
PLoS ONE, Vol 12, Iss 5, p e0178274 (2017)
Reprimo (RPRM), a member of the RPRM gene family, is a tumor-suppressor gene involved in the regulation of the p53-mediated cell cycle arrest at G2/M. RPRM has been associated with malignant tumor progression and proposed as a potential biomarker for
Externí odkaz:
https://doaj.org/article/9cbee38730524667b02d8d6c0c3629a2
Autor:
EVELYN ARANDA, GARETH I OWEN
Publikováno v:
Biological Research, Vol 42, Iss 3, Pp 377-389 (2009)
Angiogenesis, the development of new capillary vessels, has a host of clinical manifestations. The identification of agents that increase or decrease angiogenesis is of great pharmaceutical interest. Classically, in vitro angiogenesis utilizes human
Externí odkaz:
https://doaj.org/article/24d6c3c5348842db860a122531b8144f
Autor:
ANIL SADARANGANI, ANA MARÍA SALGADO, SUMIE KATO, MAURICIO PINTO, ANDRÉS CARVAJAL, CAROLINA MONSO, GARETH I OWEN, PILAR VIGIL
Publikováno v:
Biological Research, Vol 38, Iss 2-3, Pp 245-258 (2005)
Estrogen and progestin combination in hormone replacement therapy (HRT) increases the incidence of breast cancer, but decreases the endometrial cancer risk of unopposed estrogen. Therefore, a SERM such as Tibolone, that delivers the beneficial, but n
Externí odkaz:
https://doaj.org/article/f68dde2764764f77b3f8b517ebea6a0f
Publikováno v:
Biological Research, Vol 36, Iss 3-4, Pp 325-341 (2003)
The incidence of cardiovascular disease (CAD) differs between men and women, in part because of differences in risk factors and hormones. This sexual dimorphism means a lower incidence in atherosclerotic diseases in premenopausal women, which subsequ
Externí odkaz:
https://doaj.org/article/a29e4513f4244749ad36c59b9aa4ae5b
Autor:
Javiera Obreque, Luis Vergara-Gómez, Nicolás Venegas, Helga Weber, Gareth I. Owen, Pablo Pérez-Moreno, Pamela Leal, Juan Carlos Roa, Carolina Bizama
Publikováno v:
Biological Research, Vol 56, Iss 1, Pp 1-27 (2023)
Abstract In December 2022 the US Food and Drug Administration (FDA) removed the requirement that drugs in development must undergo animal testing before clinical evaluation, a declaration that now demands the establishment and verification of ex vivo
Externí odkaz:
https://doaj.org/article/53e2cfa4a35d4a9fae6d1f662c519da0
Autor:
Gareth I. Owen, Miguel Cordova-Delgado, Bernabé I. Bustos, Leslie C. Cerpa, Pamela Gonzalez, Sebastián Morales-Pison, Benjamín Garcia-Bloj, Marcelo Garrido, Juan Francisco Miquel, Luis A. Quiñones
Publikováno v:
Pharmaceutics, Vol 16, Iss 4, p 561 (2024)
Background: Pharmacogenomic knowledge as a biomarker for cancer care has transformed clinical practice, however, as current guidelines are primarily derived from Eurocentric populations, this limits their application in Latin America, particularly am
Externí odkaz:
https://doaj.org/article/7c33563f4b7e4080b31af09370753e1e
Autor:
Miguel Cordova-Delgado, María Loreto Bravo, Elisa Cumsille, Charlotte N. Hill, Matías Muñoz-Medel, Mauricio P. Pinto, Ignacio N. Retamal, María A. Lavanderos, Juan Francisco Miquel, Maria Rodriguez-Fernandez, Yuwei Liao, Zhiguang Li, Alejandro H. Corvalán, Ricardo Armisén, Marcelo Garrido, Luis A. Quiñones, Gareth I. Owen
Publikováno v:
BMC Cancer, Vol 21, Iss 1, Pp 1-18 (2021)
Abstract Background Fluoropyrimidine plus platinum chemotherapy remains the standard first line treatment for gastric cancer (GC). Guidelines exist for the clinical interpretation of four DPYD genotypes related to severe fluoropyrimidine toxicity wit
Externí odkaz:
https://doaj.org/article/63e96e3bc013444db64e630114bf6b8d
Autor:
Ignacio Niechi, José I. Erices, Diego Carrillo-Beltrán, Atenea Uribe-Ojeda, Ángelo Torres, José Dellis Rocha, Daniel Uribe, María A. Toro, Karla Villalobos-Nova, Belén Gaete-Ramírez, Gabriel Mingo, Gareth I. Owen, Manuel Varas-Godoy, Lilian Jara, Francisco Aguayo, Verónica A. Burzio, Claudia Quezada-Monrás, Julio C. Tapia
Publikováno v:
Cells, Vol 12, Iss 3, p 506 (2023)
Glioblastoma (GBM) is the most common and aggressive type of brain tumor due to its elevated recurrence following treatments. This is mainly mediated by a subpopulation of cells with stemness traits termed glioblastoma stem-like cells (GSCs), which a
Externí odkaz:
https://doaj.org/article/8da72235487e4ae7911a3687cf588995